SOX9 and posterior cortical atrophy: Previous studies have shown that transient SOX9 expression facilitates ADT resistance in PCa.[30] Another study reported that SOX9 drives WNT/β‐catenin signaling activation in PCa.[31] These results, together with our findings, suggest that a subgroup of patients with PCa would benefit from WNT‐targeted therapy alone or in combination with ADT.